Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor vs Physician's Choice in Previously Treated Myelofibrosis
NCT04562870Phase 2Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Mar 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of selinexor in myelofibrosis (MF) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Spleen Volume Reduction of >= 35% at Week 24. Started Mar 2021; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04562870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562870.